<DOC>
	<DOCNO>NCT00431353</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy safety oral Valcyte compare intravenous ganciclovir treatment CMV disease solid organ transplant recipient . Eligible patient randomize receive either 1 ) Valcyte 900mg po bid 2 ) ganciclovir 5mg/kg iv bid . The anticipated time study treatment 1-2 year target sample size 100-500 individual .</brief_summary>
	<brief_title>VICTOR Study - A Study Valcyte ( Valganciclovir po ) Compared Ganciclovir iv Patients With Cytomegalovirus ( CMV ) Disease Who Are Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>adult patient &gt; =18 year age ; recipient solid organ ( ) transplant ; virologic clinical evidence CMV disease transplantation ; patient childbearing potential must prepare use effective contraception throughout , 90 day end study . lifethreatening CMV disease accord investigator 's judgment ; pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>